FindTrial
Sign In

M-M-R II

BIOLOGICAL8 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaHaemophilus Influenzae Type bInfections, MeningococcalMeaslesMeasles-Mumps-RubellaMeasles-Mumps-Rubella VaccineMeasles; Mumps; Rubella

Phase 3

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
CompletedNCT00148941
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Tetanus
Start: 2005-01-06End: 2006-12-04Updated: 2020-02-05
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
CompletedNCT00289783
GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis
Start: 2006-02-22End: 2008-02-26Updated: 2018-08-24
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
CompletedNCT00345683
GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis
Start: 2007-07-31End: 2008-11-30Updated: 2016-11-29
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
CompletedNCT01621802
GlaxoSmithKlineMeasles-Mumps-Rubella
Start: 2012-06-21End: 2015-11-09Updated: 2019-11-25
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
CompletedNCT01681992
GlaxoSmithKlineMeasles, Measles-Mumps-Rubella Vaccine, Mumps +1
Start: 2012-10-10End: 2015-08-18Updated: 2021-01-07
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
CompletedNCT01702428
GlaxoSmithKlineMeasles, Mumps, Rubella
Start: 2012-11-09End: 2015-04-16Updated: 2019-11-25
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
CompletedNCT02184572
GlaxoSmithKlineMeasles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Start: 2014-08-25End: 2015-12-22Updated: 2021-01-07
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
CompletedNCT03621670
GlaxoSmithKlineInfections, Meningococcal
Start: 2018-07-27End: 2024-12-27Updated: 2026-02-10

Related Papers

408. Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine (PCV13) Administered Concomitantly with Routine Infant Vaccines (RIVs) to Healthy United States (US) Infants: A Randomized Controlled Study
Open Forum Infectious Diseases2026-01-01
Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates
The Journal of Infectious Diseases2019-07-1012 citations
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study
Journal of the Pediatric Infectious Diseases Society2019-02-2817 citations
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
Human Vaccines & Immunotherapeutics2019-02-2014 citations
Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study
Human Vaccines & Immunotherapeutics2018-08-1710 citations
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
2018-08-109 citations
Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials.
2012-08-017 citations
The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY).
2012-02-139 citations